0.7642

1.39% -0.0108

Karyopharm Therapeutics Inc (KPTI)

Overview News Price History Option Chain Financials Discussions Forecast

Karyopharm Therapeutics Inc stock is traded at $0.7642, with a volume of 136.02K. It is down -1.39% in the last 24 hours and down -10.56% over the past month. Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Previous Close:

$0.775

Open:

$0.76

24h Volume:

136.02K

Relative Volume:

0.18

Market Cap:

$97.77M

Revenue:

$140.46M

Net Income/Loss:

$-146.34M

P/E Ratio:

-0.5789

EPS:

-1.32

Net Cash Flow:

$-117.73M

1W Performance:

-8.73%

1M Performance:

-10.56%

6M Performance:

-31.77%

1Y Performance:

+3.52%

1-Day Range:

$0.76

$0.798

1-Week Range:

$0.7518

$0.8886

52-Week Range:

$0.6174

$1.95

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name

Karyopharm Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

617-658-0600

Address

85 WELLS AVENUE, NEWTON, MA

Employee

325

Twitter

@Karyopharm

Next Earnings Date

2024-11-05

Latest SEC Filings

KPTI's Discussions on Twitter

Compare KPTI with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KPTI	0.77	97.77M	140.46M	-146.34M	-117.73M	-1.32
VRTX	446.78	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	738.30	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	586.52	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.35	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.55	24.49B	3.30B	-501.07M	1.03B	11.54

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-19-23	Initiated	Piper Sandler	Overweight
Nov-04-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Feb-09-22	Upgrade	JP Morgan	Underweight → Neutral
Nov-19-21	Resumed	Morgan Stanley	Equal-Weight
Aug-06-21	Downgrade	JP Morgan	Overweight → Neutral
Aug-06-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-06-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jul-02-20	Initiated	Morgan Stanley	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Jan-17-20	Downgrade	Wedbush	Outperform → Neutral
Jul-23-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-05-19	Reiterated	H.C. Wainwright	Buy
Jul-05-19	Reiterated	Robert W. Baird	Outperform
Mar-01-19	Downgrade	JP Morgan	Overweight → Neutral
Feb-28-19	Reiterated	BofA/Merrill	Underperform
Feb-27-19	Downgrade	BofA/Merrill	Neutral → Underperform
Jan-03-19	Upgrade	BofA/Merrill	Underperform → Neutral
Dec-03-18	Initiated	B. Riley FBR	Buy
Nov-09-18	Upgrade	Wedbush	Neutral → Outperform
May-24-18	Downgrade	Wedbush	Outperform → Neutral
Apr-02-18	Resumed	Leerink Partners	Outperform
Nov-15-17	Resumed	H.C. Wainwright	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-08-16	Reiterated	H.C. Wainwright	Buy
Aug-30-16	Upgrade	Jefferies	Hold → Buy
Aug-18-16	Initiated	H.C. Wainwright	Buy
Jun-28-16	Initiated	Robert W. Baird	Outperform

View All

Karyopharm Therapeutics Inc Stock (KPTI) Latest News

03:42 AM

Karyopharm appoints new chief accounting officer By Investing.com - Investing.com UK

Nov 20, 2024

Karyopharm Therapeutics Inc. Appoints Kristin Abate as Chief Accounting Officer - Marketscreener.com

Nov 20, 2024

Nov 18, 2024

Karyopharm to Present Selinexor Data at the 66th American Society of Hematology Annual Meeting and Exposition - PR Newswire

Nov 18, 2024

Nov 15, 2024

Avidity Partners Management LP's Strategic Acquisition of Karyop - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com Nigeria

Nov 14, 2024

Karyopharm Therapeutics' SWOT analysis: stock outlook amid pipeline progress - Investing.com India

Nov 14, 2024

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Rating Upgraded by StockNews.com - MarketBeat

Nov 14, 2024

GSA Capital Partners LLP Purchases 792,283 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat

Nov 14, 2024

Nov 08, 2024

Leerink Partnrs Issues Optimistic Forecast for KPTI Earnings - MarketBeat

Nov 08, 2024

What is HC Wainwright's Estimate for KPTI FY2024 Earnings? - MarketBeat

Nov 08, 2024

Karyopharm Therapeutics Falls To US$0.88, But Insiders Sold At Lower Price - Simply Wall St

Nov 08, 2024

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance

Nov 08, 2024

Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Expected to Rise, Piper Sandler Analyst Says - Defense World

Nov 08, 2024

Karyopharm Therapeutics Reports Q3 2024 Financial Results and Corporate Progress - Defense World

Nov 08, 2024

Nov 07, 2024